Stemline Therapeutics B.V. - Resultados de la búsqueda

Unión Europea - español - EMA (European Medicines Agency)

elzonris

stemline therapeutics b.v. - tagraxofusp - lymphoma - agentes antineoplásicos - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Unión Europea - español - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - neoplasias de la mama - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Unión Europea - español - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - mieloma múltiple - agentes antineoplásicos - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

stellige 100 mg comprimidos recubiertos con pelicula

novartis farmaceutica, s.a. - lumiracoxib - excipientes: lactosa monohidrato,croscarmelosa sodica - productos antiinflamatorios y antirreumÁticos no esteroideos - coxibs - lumiracoxib